Efficacy and safety of enavogliflozin vs. dapagliflozin as add-on therapy in patients with type 2 diabetes mellitus based on renal function: a pooled analysis of two randomized controlled trials

Efficacy and safety of enavogliflozin vs. dapagliflozin as add-on therapy in patients with type 2 diabetes mellitus based on renal function: a pooled analysis of two randomized controlled trials

Abstract Background We assessed the efficacy and safety of enavogliflozin (0.3 mg), a newly developed SGLT-2 inhibitor, in patients with type 2 diabetes mellitus based on kidney function via pooled analysis of two 24-week, randomized, double-blind phase III trials. Methods Data from 470 patients wer...

Full description

Bibliographic Details
Main Authors: Young Sang Lyu, Sangmo Hong, Si Eun Lee, Bo Young Cho, Cheol-Young Park
Format: Article
Language:English
Published: BMC 2024-02-01
Series:Cardiovascular Diabetology
Subjects:
Enavogliflozin
Glycemic control
Non-insulin dependent diabetes mellitus
SGLT-2 inhibitor
Urine glucose excretion rate
Online Access:https://doi.org/10.1186/s12933-024-02155-9

Internet

https://doi.org/10.1186/s12933-024-02155-9

Similar Items